In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to achieve breakthroughs in Alzheimer’s disease research, in an aim to alter disease progression before daily life is significantly affected.